Click on image to view larger version.

Figure 5 The PRavastatin Or atorVastatin Evaluation and Infection Therapy (PROVE-IT) trial randomized over 4,000 patients either to high-dose atorvastatin (low-density lipoprotein [LDL] = 62 mg/dl) or pravastatin (LDL = 95 mg/dl) (12). A 16% reduction in the primary end point was noted in the atorvastatin-treated group.